Actively Recruiting
OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
Led by Gangnam Severance Hospital · Updated on 2025-05-22
418
Participants Needed
2
Research Sites
516 weeks
Total Duration
On this page
Sponsors
G
Gangnam Severance Hospital
Lead Sponsor
S
Seoul National University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.
CONDITIONS
Official Title
OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with estrogen receptor-positive, HER2-negative breast cancer
- Premenopausal and aged 50 years or younger
- Tumor size classified as T1 or T2
- Cancer present in lymph nodes classified as N1, including micrometastasis
- Genomic low risk score (1-20) based on OncoFREE4 multigene test
You will not qualify if you...
- Postmenopausal women
- Women with estrogen receptor-negative breast cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Gangnam Severance Hospital
Seoul, Korea, South Korea, 06229
Actively Recruiting
2
Seoul National University Hospital
Seoul, South Korea
Not Yet Recruiting
Research Team
S
Sung Gwe Ahn, M.D.,Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here